Eli Lilly to Acquire Scorpion Therapeutics’ PI3Kα Inhibitor STX-478 for Advanced Solid Tumors

 Eli Lilly and Company (NYSE: LLY) and Scorpion Therapeutics, Inc. ("Scorpion"), a private biotechnology company developing small ...

January 14, 2025 | Tuesday | News
AbbVie and Simcere Zaiming Partner to Develop SIM0500 for Relapsed/Refractory Multiple Myeloma

NORTH CHICAGO, Ill. and SHANGHAI, AbbVie (NYSE: ABBV) and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) ann...

January 14, 2025 | Tuesday | News
GSK to Acquire IDRx for $1 Billion to Advance Precision Therapies for GIST

GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx)  announced that they have entered into an agreement under which GSK will acquire IDRx, a Boston-based, c...

January 14, 2025 | Tuesday | News
AstraZeneca and Daiichi Sankyo’s Datopotamab Deruxtecan (Dato-DXd) Receives FDA Priority Review for EGFR-Mutated Non-Small Cell Lung Cancer

AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted and granted Priority Rev...

January 14, 2025 | Tuesday | News
China Approves Sarclisa for Relapsed/Refractory Multiple Myeloma, Expanding Treatment Options

The National Medical Products Administration (NMPA) in China has approved Sarclisa, an anti-CD38 medicine, in combination with pomalidomide and dexamethaso...

January 14, 2025 | Tuesday | News
Bioxytran Publishes Groundbreaking Research on Galectin-3 Modulation to Enhance Cancer Immunotherapy Efficacy

BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral dise...

January 14, 2025 | Tuesday | News
HMNC Brain Health Reaches Key Milestone with Successful Patient Randomization in Phase 2b OLIVE Trial for Major Depressive Disorder

HMNC Brain Health (“HMNC”), a clinical-stage precision psychiatry biopharma company pioneering personalized treatments powered by predictive co...

January 14, 2025 | Tuesday | News
Vertex Pharmaceuticals and Zai Lab Announce Exclusive Collaboration for Development and Commercialization of Povetacicept in Asia

-Vertex Pharmaceuticals Incorporated  and Zai Lab Limited announced an exclusive collaboration and license agreement for the development a...

January 13, 2025 | Monday | News
Menarini and Stemline Secure Global Rights to Innovative Oncology Small Molecule in Partnership with Insilico Medicine

The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-own...

January 13, 2025 | Monday | News
Kardigan Launches with $300 Million Series A to Transform Cardiovascular Disease Treatment

Company embarks on a vision to make cardiovascular disease curable, preventable, and no longer the leading cause of death worldwide Led by found...

January 13, 2025 | Monday | News
Gilead Sciences and LEO Pharma Form Strategic Partnership to Advance STAT6 Oral Therapies for Inflammatory Diseases

-Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma  announced a strategic partnership to accelerate the development and commercializatio...

January 13, 2025 | Monday | News
Windward Bio Launches with $200M Series A Financing to Develop Breakthrough Immunology Treatments

Windward Bio, a private, clinical-stage, drug development company committed to improving outcomes for people living with advanced immunological diseases, a...

January 12, 2025 | Sunday | News
Zai Lab and MediLink Forge Global Partnership to Develop Groundbreaking LRRC15 ADC Therapy

Zai Lab Limited announced a new strategic collaboration and worldwide license agreement with MediLink Therapeutics (Suzhou) Co., Ltd.  to use MediLi...

January 13, 2025 | Monday | News
Partner Therapeutics Partners with BARDA to Fund Phase 2 Study of LEUKINE in Sepsis Patients

Partner Therapeutics, Inc. (PTx) announced a collaboration with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administrat...

January 10, 2025 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close